Chief Development Officer & SAB Chair 

Gavin Corcoran, MD FACP

As Chief Development Officer (CDO) at Formation Bio, Gavin is an experienced drug development innovator, strategist, and business builder. With previous roles including Chief R&D Officer at Axovant Gene Therapies and Chief Medical Officer at Allergan, his expertise spans therapeutic areas like CNS, CV, Dermatology, and Respiratory, boasting over 20 approvals worldwide. Gavin is Board Certified in Infectious diseases and Internal Medicine and is an enthusiastic integrator of AI into Drug Development. 

Professor of Research, Genetic Medicine

Dolan Sondhi, Ph.D

Dr. Sondhi is a highly accomplished research scientist with over two decades of experience in all aspects of clinical translation of AAV gene therapies for genetic disorders, focusing on CNS and metabolic diseases. She is a Professor of Research in Genetic Medicine, Associate Director of the Gene Therapy Core Facility at Weill Cornell Medicine and serves on corporate and scientific advisory boards. Dr. Sondhi holds a Ph.D. from Brown University.

Strategy and Program & Portfolio Management 

Roberta Duncan, MBA

Roberta Duncan, Chief Stratergy Officer at Arcturus Tx and Vice Chair of the Alliance for mRNA Medicines, has over 25 years in biopharma. Specializing in vaccine and drug development, she's skilled in asset strategy, R&D, strategic planning, and diverse therapeutic product development. Her experience spans CSL, Shire, Trevi Therapeutics, BMS, Kendle International, and Eli Lilly. Duncan holds a BA in Biochemistry and a dual MBA.

CEO & Venture Partner

Kent Rogers, MBA

Kent Rogers is the President of CarelonRx and previous CEO of EveryONE Medicines, a Venture Partner at ARCH, and serves on the board of SlateRx. With over 30 years in product commercialization, supply chain logistics, pricing, market access, and growth strategies, he is a seasoned executive. Previously, he was the CCO of EQRx, leading pre-commercialization strategies. At OptumRx, he managed $40 billion in annual rebate agreements and over $16 billion in specialty med procurement for Optum Specialty Pharmacy. Kent also held leadership roles at Acorda Therapeutics, Schering-Plough, and Merck. He has served in multiple advisory roles for pharmaceutical firms, payer organizations and the National Business Group on Health. He has a B.S. from Indiana University and an M.B.A. from Emory University. 

R&D Leader. Platform & Asset Strategy

Sara Cortese, PhD

Sara Cortese is a pharmaceutical R&D leader with 20 years’ experience in the discovery of clinical candidates across multiple diseases. As president of SwipeRightBio-tech, she advises startups, biotechs, and VCs in asset and platform strategies. As a Managing Director at Accenture, she built strategies enabling AI in R&D, including an AI-driven personalized medicine solution. Her expertise from leadership roles at GSK, Roche and Accenture are crucial for Intelisci’s client support for commercializing Biotech innovation.

Human Resources Executive & Start up Advisor

Ann Corkum, MBA

Ann brings over 25 years of HR leadership to support startup and growing life sciences companies with practical, business-driven people strategies. She partners with founders, executives and investors on leadership development, team design, and resource planning, ensuring organizations scale with intention and clarity. With experience across global pharma and across industries, Ann combines coaching, business logic, and a bias for simplicity to solve complex challenges. She thrives on impact, transformation, and helping teams build strong foundations from the start.

Translational Medicine & Clinical Development

Erika De Boever, PhD 

Erika De Boever, has over 20 years in the pharmaceutical and biotech sectors, specializes in gene therapies and has held leadership roles at uPenn, Sio Gene Therapies, and GSK. Notably, she contributed to the approval of Strimvelis for ADASCID at GSK. Her expertise in gene therapy and rare diseases is crucial for Intelisci, enhancing client support for clinical transitions.

CMC & Manufacturing 

Kirsten Pier, MBA

Kirsten Pier, holds 18 years in CMC, specializes in process development and manufacturing for clinical and commercial sectors. At TKD Solutions, she leads operations, offering expertise in biotech products. Her background includes senior roles at Sio Gene Therapies, Bluebird Bio, Shire, and Amgen, covering research to commercial phase development. Her insights significantly enhance our CMC candidate delivery.

Immunology/Inflammatory Product Development

Neil Wishart, PhD

Neil Wishart, is a Global Biopharma Executive with three decades of exceptional leadership. Known for pioneering approaches in I&I, he has played pivotal roles at AbbVie Bioresearch Center, contributing to groundbreaking immunology therapies like RinvoqTM (upadacitinib). Neil led the development of immunology and inflammation programs at EQRx, which successfully went public during his tenure via SPAC. Neil is currently VP Clinical Strategy at Celldex. 

Commercial & Business Development

Rod Cameron, PHD

Rod, founder of CamPharm Consulting Group, is a leading expert in outsourcing, technology transfer, and business strategy. His 22-year career includes significant roles at BMS, Sanofi Pasteur, and Merck, focusing on strategic licensing in oncology and immunology. He specializes in managing large-scale outsourcing and capital projects. Rod holds two Chemistry PhDs from the University of Cambridge.

Lipid Nanoparticles & Parenteral Drug Expert 

Alexander Aust, MA, MBA

Alex, a peerless expert in cell and gene therapy, has extensive experience in commercializing and manufacturing complex drug products, including lipid nanoparticles. Alex is founder of Aust Business Solutions and holds an MBA from Ball State and an MS in Molecular and Cellular Biology from Purdue University, and previously led Business Development at Exelead Biopharma.

Advanced Clinical Stage Oncology Strategy 

Rob Drury-Dryden, MBA

Rob, founder of Precision Biopharma Consultancy, specializes in oncology drug development, with a focus on biomarker-led therapies. His 17-year career spans AstraZeneca (Lyparza), Merck Serono (Erbitux), and Janssen (Balversa, Zytiga, Erleada). Rob holds an MSc in Biochemistry and an MBA, leading with innovation and focusing on organizational design and charity through sports.